DOJ Subpoenas Merck Over Avelox, Integrilin Marketing

Law360, New York (November 9, 2011, 7:58 PM EST) -- The U.S. Department of Justice has subpoenaed Merck & Co. Inc. for information on its marketing practices for heart medication Integrilin and antibiotic Avelox and is investigating one of its subsidiaries for off-label marketing of a third drug, the drugmaker said Tuesday.

The New Jersey-based drugmaker said in a regulatory filing that the U.S. Department of Justice issued a subpoena for information about the marketing of Avelox, which is used to treat respiratory and skin infections, and Integrilin, which prevents blood clots, from January 2003 to...
To view the full article, register now.